



Xeljanz (tofacitnib) Drug Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-22	111	PDF

Single User	Multi User	Enterprise
USD 2,950	USD 4,430	USD 5,900

Description

The global Xeljanz (tofacitnib) Drug market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Xeljanz (tofacitnib) Drug is projected to increase from US\$ million in 2026 to US\$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Xeljanz (tofacitnib) Drug is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032.

The Asia Pacific market for Xeljanz (tofacitnib) Drug is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Xeljanz (tofacitnib) Drug include Pfizer. among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Xeljanz (tofacitnib) Drug market in terms of revenue (US\$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US\$/k units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Xeljanz (tofacitnib) Drug Market by Company

Pfizer

Xeljanz (tofacitnib) Drug Segment by Type

Tablets

Extended-release Tablets

Xeljanz (tofacitnib) Drug Segment by Application

Rheumatoid Arthritis

Psoriatic Arthritis

Other

Xeljanz (tofacitnib) Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Xeljanz (tofacitinib) Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Xeljanz (tofacitinib) Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Xeljanz (tofacitinib) Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Detailed analysis of Xeljanz (tofacitinib) Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5:

Production/output, value of Xeljanz (tofacitinib) Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6:

Consumption of Xeljanz (tofacitinib) Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7:

Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8:

Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9:

Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10:

Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
 - 2.2.1 Global Xeljanz (tofacitnib) Drug Market Size (2021-2032)
 - 2.2.2 Global Xeljanz (tofacitnib) Drug Sales (2021-2032)
 - 2.2.3 Global Xeljanz (tofacitnib) Drug Market Average Price (2021-2032)
- 2.3 Xeljanz (tofacitnib) Drug by Type
 - 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
 - 2.3.2 Tablets
 - 2.3.3 Extended-release Tablets
- 2.4 Xeljanz (tofacitnib) Drug by Application
 - 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.4.2 Rheumatoid Arthritis
 - 2.4.3 Psoriatic Arthritis
 - 2.4.4 Other

3 Market Competitive Landscape by Manufacturers

- 3.1 Global Xeljanz (tofacitnib) Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Xeljanz (tofacitnib) Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global Xeljanz (tofacitnib) Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Xeljanz (tofacitnib) Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Xeljanz (tofacitnib) Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Xeljanz (tofacitnib) Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Xeljanz (tofacitnib) Drug, Product Type & Application
- 3.8 Global Manufacturers of Xeljanz (tofacitnib) Drug, Established Date
- 3.9 Global Xeljanz (tofacitnib) Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition

4 Manufacturers Profiled

- 4.1 Pfizer
 - 4.1.1 Pfizer Company Information
 - 4.1.2 Pfizer Business Overview
 - 4.1.3 Pfizer Xeljanz (tofacitnib) Drug Sales, Revenue and Gross Margin (2021-2026)
 - 4.1.4 Pfizer Xeljanz (tofacitnib) Drug Product Portfolio
 - 4.1.5 Pfizer Recent Developments

5 Global Xeljanz (tofacitnib) Drug Market Scenario by Region

- 5.1 Global Xeljanz (tofacitnib) Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Xeljanz (tofacitnib) Drug Sales by Region: 2021-2032
 - 5.2.1 Global Xeljanz (tofacitnib) Drug Sales by Region: 2021-2026
 - 5.2.2 Global Xeljanz (tofacitnib) Drug Sales by Region: 2027-2032
- 5.3 Global Xeljanz (tofacitnib) Drug Revenue by Region: 2021-2032
 - 5.3.1 Global Xeljanz (tofacitnib) Drug Revenue by Region: 2021-2026
 - 5.3.2 Global Xeljanz (tofacitnib) Drug Revenue by Region: 2027-2032
- 5.4 North America Xeljanz (tofacitnib) Drug Market Facts & Figures by Country
 - 5.4.1 North America Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.4.2 North America Xeljanz (tofacitnib) Drug Sales by Country (2021-2032)
 - 5.4.3 North America Xeljanz (tofacitnib) Drug Revenue by Country (2021-2032)
 - 5.4.4 United States
 - 5.4.5 Canada
 - 5.4.6 Mexico
- 5.5 Europe Xeljanz (tofacitnib) Drug Market Facts & Figures by Country
 - 5.5.1 Europe Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.5.2 Europe Xeljanz (tofacitnib) Drug Sales by Country (2021-2032)
 - 5.5.3 Europe Xeljanz (tofacitnib) Drug Revenue by Country (2021-2032)
 - 5.5.4 Germany
 - 5.5.5 France
 - 5.5.6 U.K.
 - 5.5.7 Italy
 - 5.5.8 Russia
 - 5.5.9 Spain
 - 5.5.10 Netherlands
 - 5.5.11 Switzerland
 - 5.5.12 Sweden
 - 5.5.13 Poland
- 5.6 Asia Pacific Xeljanz (tofacitnib) Drug Market Facts & Figures by Country
 - 5.6.1 Asia Pacific Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.6.2 Asia Pacific Xeljanz (tofacitnib) Drug Sales by Country (2021-2032)
 - 5.6.3 Asia Pacific Xeljanz (tofacitnib) Drug Revenue by Country (2021-2032)
 - 5.6.4 China
 - 5.6.5 Japan
 - 5.6.6 South Korea
 - 5.6.7 India
 - 5.6.8 Australia
 - 5.6.9 Taiwan
 - 5.6.10 Southeast Asia
- 5.7 South America Xeljanz (tofacitnib) Drug Market Facts & Figures by Country
 - 5.7.1 South America Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032
 - 5.7.2 South America Xeljanz (tofacitnib) Drug Sales by Country (2021-2032)
 - 5.7.3 South America Xeljanz (tofacitnib) Drug Revenue by Country (2021-2032)
 - 5.7.4 Brazil
 - 5.7.5 Argentina
 - 5.7.6 Chile
- 5.8 Middle East and Africa Xeljanz (tofacitnib) Drug Market Facts & Figures by Country
 - 5.8.1 Middle East and Africa Xeljanz (tofacitnib) Drug Market Size by Country: 2021 VS 2025 VS 2032

- 5.8.2 Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2021-2032)
 - 5.8.3 Middle East and Africa Xeljanz (tofacitnib) Drug Revenue by Country (2021-2032)
 - 5.8.4 Egypt
 - 5.8.5 South Africa
 - 5.8.6 Israel
 - 5.8.7 Türkiye
 - 5.8.8 GCC Countries
-

6 Segment by Type

- 6.1 Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2032)
 - 6.1.1 Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2032) & (k units)
 - 6.1.2 Global Xeljanz (tofacitnib) Drug Sales Market Share by Type (2021-2032)
 - 6.2 Global Xeljanz (tofacitnib) Drug Revenue by Type (2021-2032)
 - 6.2.1 Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2032) & (US\$ Million)
 - 6.2.2 Global Xeljanz (tofacitnib) Drug Revenue Market Share by Type (2021-2032)
 - 6.3 Global Xeljanz (tofacitnib) Drug Price by Type (2021-2032)
-

7 Segment by Application

- 7.1 Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2032)
 - 7.1.1 Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2032) & (k units)
 - 7.1.2 Global Xeljanz (tofacitnib) Drug Sales Market Share by Application (2021-2032)
 - 7.2 Global Xeljanz (tofacitnib) Drug Revenue by Application (2021-2032)
 - 7.2.1 Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2032) & (US\$ Million)
 - 7.2.2 Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application (2021-2032)
 - 7.3 Global Xeljanz (tofacitnib) Drug Price by Application (2021-2032)
-

8 Value Chain and Sales Channels Analysis of the Market

- 8.1 Xeljanz (tofacitnib) Drug Value Chain Analysis
 - 8.1.1 Xeljanz (tofacitnib) Drug Key Raw Materials
 - 8.1.2 Raw Materials Key Suppliers
 - 8.1.3 Xeljanz (tofacitnib) Drug Production Mode & Process
 - 8.2 Xeljanz (tofacitnib) Drug Sales Channels Analysis
 - 8.2.1 Direct Comparison with Distribution Share
 - 8.2.2 Xeljanz (tofacitnib) Drug Distributors
 - 8.2.3 Xeljanz (tofacitnib) Drug Customers
-

9 Global Xeljanz (tofacitnib) Drug Analyzing Market Dynamics

- 9.1 Xeljanz (tofacitnib) Drug Industry Trends
 - 9.2 Xeljanz (tofacitnib) Drug Industry Drivers
 - 9.3 Xeljanz (tofacitnib) Drug Industry Opportunities and Challenges
 - 9.4 Xeljanz (tofacitnib) Drug Industry Restraints
-

10 Report Conclusion

11 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Xeljanz (tofacitnib) Drug Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025)
- Table 6: Global Xeljanz (tofacitnib) Drug Sales (k units) of Manufacturers (2021-2026)
- Table 7: Global Xeljanz (tofacitnib) Drug Sales Market Share by Manufacturers (2021-2026)
- Table 8: Global Xeljanz (tofacitnib) Drug Revenue of Manufacturers (2021-2026)
- Table 9: Global Xeljanz (tofacitnib) Drug Revenue Share by Manufacturers (2021-2026)
- Table 10: Global Market Xeljanz (tofacitnib) Drug Average Price (US\$/unit) of Manufacturers (2021-2026)
- Table 11: Global Xeljanz (tofacitnib) Drug Industry Ranking, 2024 VS 2025 VS 2026
- Table 12: Global Manufacturers of Xeljanz (tofacitnib) Drug, Manufacturing Sites & Headquarters
- Table 13: Global Manufacturers of Xeljanz (tofacitnib) Drug, Product Type & Application
- Table 14: Global Xeljanz (tofacitnib) Drug Manufacturers Established Date
- Table 15: Global Manufacturers Market Concentration Ratio (CR5 and HHI)
- Table 16: Global Xeljanz (tofacitnib) Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 17: Manufacturers Mergers & Acquisitions, Expansion Plans)
- Table 18: Pfizer Company Information
- Table 19: Pfizer Business Overview
- Table 20: Pfizer Xeljanz (tofacitnib) Drug Sales (k units), Revenue (US\$ Million), Price (US\$/unit) and Gross Margin (2021-2026)
- Table 21: Pfizer Xeljanz (tofacitnib) Drug Product Portfolio
- Table 22: Pfizer Recent Developments
- Table 23: Global Xeljanz (tofacitnib) Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 24: Global Xeljanz (tofacitnib) Drug Sales by Region (2021-2026) & (k units)
- Table 25: Global Xeljanz (tofacitnib) Drug Sales Market Share by Region (2021-2026)
- Table 26: Global Xeljanz (tofacitnib) Drug Sales by Region (2027-2032) & (k units)
- Table 27: Global Xeljanz (tofacitnib) Drug Sales Market Share by Region (2027-2032)
- Table 28: Global Xeljanz (tofacitnib) Drug Revenue by Region (2021-2026) & (US\$ Million)
- Table 29: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Region (2021-2026)
- Table 30: Global Xeljanz (tofacitnib) Drug Revenue by Region (2027-2032) & (US\$ Million)
- Table 31: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Region (2027-2032)
- Table 32: North America Xeljanz (tofacitnib) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 33: North America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units)
- Table 34: North America Xeljanz (tofacitnib) Drug Sales by Country (2027-2032) & (k units)
- Table 35: North America Xeljanz (tofacitnib) Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 36: North America Xeljanz (tofacitnib) Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 37: Europe Xeljanz (tofacitnib) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 38: Europe Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units)
- Table 39: Europe Xeljanz (tofacitnib) Drug Sales by Country (2027-2032) & (k units)
- Table 40: Europe Xeljanz (tofacitnib) Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 41: Europe Xeljanz (tofacitnib) Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 42: Asia Pacific Xeljanz (tofacitnib) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Asia Pacific Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units)
- Table 44: Asia Pacific Xeljanz (tofacitnib) Drug Sales by Country (2027-2032) & (k units)
- Table 45: Asia Pacific Xeljanz (tofacitnib) Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 46: Asia Pacific Xeljanz (tofacitnib) Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 47: South America Xeljanz (tofacitnib) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 48: South America Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units)
- Table 49: South America Xeljanz (tofacitnib) Drug Sales by Country (2027-2032) & (k units)
- Table 50: South America Xeljanz (tofacitnib) Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 51: South America Xeljanz (tofacitnib) Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 52: Middle East and Africa Xeljanz (tofacitnib) Drug Revenue by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 53: Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2021-2026) & (k units)
- Table 54: Middle East and Africa Xeljanz (tofacitnib) Drug Sales by Country (2027-2032) & (k units)

- Table 55: Middle East and Africa Xeljanz (tofacitnib) Drug Revenue by Country (2021-2026) & (US\$ Million)
- Table 56: Middle East and Africa Xeljanz (tofacitnib) Drug Revenue by Country (2027-2032) & (US\$ Million)
- Table 57: Global Xeljanz (tofacitnib) Drug Sales by Type (2021-2026) & (k units)
- Table 58: Global Xeljanz (tofacitnib) Drug Sales by Type (2027-2032) & (k units)
- Table 59: Global Xeljanz (tofacitnib) Drug Sales Market Share by Type (2021-2026)
- Table 60: Global Xeljanz (tofacitnib) Drug Sales Market Share by Type (2027-2032)
- Table 61: Global Xeljanz (tofacitnib) Drug Revenue by Type (2021-2026) & (US\$ Million)
- Table 62: Global Xeljanz (tofacitnib) Drug Revenue by Type (2027-2032) & (US\$ Million)
- Table 63: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Type (2021-2026)
- Table 64: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Type (2027-2032)
- Table 65: Global Xeljanz (tofacitnib) Drug Price by Type (2021-2026) & (US\$/unit)
- Table 66: Global Xeljanz (tofacitnib) Drug Price by Type (2027-2032) & (US\$/unit)
- Table 67: Global Xeljanz (tofacitnib) Drug Sales by Application (2021-2026) & (k units)
- Table 68: Global Xeljanz (tofacitnib) Drug Sales by Application (2027-2032) & (k units)
- Table 69: Global Xeljanz (tofacitnib) Drug Sales Market Share by Application (2021-2026)
- Table 70: Global Xeljanz (tofacitnib) Drug Sales Market Share by Application (2027-2032)
- Table 71: Global Xeljanz (tofacitnib) Drug Revenue by Application (2021-2026) & (US\$ Million)
- Table 72: Global Xeljanz (tofacitnib) Drug Revenue by Application (2027-2032) & (US\$ Million)
- Table 73: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application (2021-2026)
- Table 74: Global Xeljanz (tofacitnib) Drug Revenue Market Share by Application (2027-2032)
- Table 75: Global Xeljanz (tofacitnib) Drug Price by Application (2021-2026) & (US\$/unit)
- Table 76: Global Xeljanz (tofacitnib) Drug Price by Application (2027-2032) & (US\$/unit)
- Table 77: Key Raw Materials
- Table 78: Raw Materials Key Suppliers
- Table 79: Xeljanz (tofacitnib) Drug Distributors List
- Table 80: Xeljanz (tofacitnib) Drug Customers List
- Table 81: Xeljanz (tofacitnib) Drug Industry Trends
- Table 82: Xeljanz (tofacitnib) Drug Industry Drivers
- Table 83: Xeljanz (tofacitnib) Drug Industry Restraints
- Table 84: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Xeljanz (tofacitnib) Drug Product Image
- Figure 5: Global Xeljanz (tofacitnib) Drug Revenue (US\$ Million), 2021 VS 2025 VS 2032
- Figure 6: Global Xeljanz (tofacitnib) Drug Market Size (2021-2032) & (US\$ Million)
- Figure 7: Global Xeljanz (tofacitnib) Drug Sales (2021-2032) & (k units)
- Figure 8: Global Xeljanz (tofacitnib) Drug Average Price (US\$/unit) & (2021-2032)
- Figure 9: Tablets Product Image
- Figure 10: Extended-release Tablets Product Image
- Figure 11: Rheumatoid Arthritis Product Image
- Figure 12: Psoriatic Arthritis Product Image
- Figure 13: Other Product Image
- Figure 14: Global Xeljanz (tofacitnib) Drug Revenue Share by Manufacturers in 2025
- Figure 15: Global Manufacturers of Xeljanz (tofacitnib) Drug, Manufacturing Sites & Headquarters
- Figure 16: Global Top 5 and 10 Xeljanz (tofacitnib) Drug Players Market Share by Revenue in 2025
- Figure 17: Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 18: Global Xeljanz (tofacitnib) Drug Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Figure 19: Global Xeljanz (tofacitnib) Drug Sales by Region in 2025
- Figure 20: Global Xeljanz (tofacitnib) Drug Revenue by Region in 2025
- Figure 21: North America Xeljanz (tofacitnib) Drug Market Size by Country in 2025
- Figure 22: North America Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2032)
- Figure 23: North America Xeljanz (tofacitnib) Drug Revenue Market Share by Country (2021-2032)
- Figure 24: United States Xeljanz (tofacitnib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 25: Canada Xeljanz (tofacitnib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 26: Mexico Xeljanz (tofacitnib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 27: Europe Xeljanz (tofacitnib) Drug Market Size by Country in 2025
- Figure 28: Europe Xeljanz (tofacitnib) Drug Sales Market Share by Country (2021-2032)
- Figure 29: Europe Xeljanz (tofacitnib) Drug Revenue Market Share by Country (2021-2032)
- Figure 30: Germany Xeljanz (tofacitnib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 31: France Xeljanz (tofacitnib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)

- Figure 32: U.K. Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 33: Italy Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 34: Russia Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 35: Spain Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 36: Netherlands Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 37: Switzerland Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 38: Sweden Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 39: Poland Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 40: Asia Pacific Xeljanz (tofacitinib) Drug Market Size by Country in 2025
- Figure 41: Asia Pacific Xeljanz (tofacitinib) Drug Sales Market Share by Country (2021-2032)
- Figure 42: Asia Pacific Xeljanz (tofacitinib) Drug Revenue Market Share by Country (2021-2032)
- Figure 43: China Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 44: Japan Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 45: South Korea Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 46: India Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 47: Australia Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 48: Taiwan Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 49: Southeast Asia Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 50: Southeast Asia Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 51: South America Xeljanz (tofacitinib) Drug Market Size by Country in 2025
- Figure 52: South America Xeljanz (tofacitinib) Drug Sales Market Share by Country (2021-2032)
- Figure 53: South America Xeljanz (tofacitinib) Drug Revenue Market Share by Country (2021-2032)
- Figure 54: Brazil Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 55: Argentina Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 56: Chile Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 57: Middle East and Africa Xeljanz (tofacitinib) Drug Market Size by Country in 2025
- Figure 58: Middle East and Africa Xeljanz (tofacitinib) Drug Sales Market Share by Country (2021-2032)
- Figure 59: Middle East and Africa Xeljanz (tofacitinib) Drug Revenue Market Share by Country (2021-2032)
- Figure 60: Egypt Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 61: South Africa Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 62: Israel Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 63: Türkiye Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 64: GCC Countries Xeljanz (tofacitinib) Drug Revenue Growth Rate (2021-2032) & (US\$ Million)
- Figure 65: Global Xeljanz (tofacitinib) Drug Sales Market Share by Type (2021-2032)
- Figure 66: Global Xeljanz (tofacitinib) Drug Revenue Market Share by Type (2021-2032)
- Figure 67: Global Xeljanz (tofacitinib) Drug Price (US\$/unit) by Type (2021-2032)
- Figure 68: Global Xeljanz (tofacitinib) Drug Sales Market Share by Application (2021-2032)
- Figure 69: Global Xeljanz (tofacitinib) Drug Revenue Market Share by Application (2021-2032)
- Figure 70: Global Xeljanz (tofacitinib) Drug Price (US\$/unit) by Application (2021-2032)
- Figure 71: Xeljanz (tofacitinib) Drug Value Chain
- Figure 72: Xeljanz (tofacitinib) Drug Production Mode & Process
- Figure 73: Direct Comparison with Distribution Share
- Figure 74: Distributors Profiles
- Figure 75: Xeljanz (tofacitinib) Drug Industry Opportunities and Challenges